Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results
- Top-line safety and pharmacokinetic data expected in H1 2025 from recently initiated single ascending dose trial of anti-tau antibody for Alzheimer’s disease - - Three CNS gene therapy programs on track for INDs in 2025 following development candidate …